These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28617895)

  • 61. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C.
    Adinolfi LE; Rinaldi L; Marrone A; Giordano M
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):595-597. PubMed ID: 30047799
    [No Abstract]   [Full Text] [Related]  

  • 62. What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
    Kim JW
    J Korean Med Sci; 2019 Oct; 34(41):e277. PubMed ID: 31650721
    [No Abstract]   [Full Text] [Related]  

  • 63. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The remaining challenges of HCV treatment in the direct-acting antivirals era.
    Kim BK; Ahn SH
    J Gastroenterol Hepatol; 2019 Nov; 34(11):1891-1892. PubMed ID: 31724229
    [No Abstract]   [Full Text] [Related]  

  • 65. Curing hepatitis C with pills: a step toward global control.
    Thomas DL
    Lancet; 2010 Oct; 376(9751):1441-2. PubMed ID: 20951421
    [No Abstract]   [Full Text] [Related]  

  • 66. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY.
    Torres AD; Sparvoli JMH; Sparvoli AC; Gonçalves CV
    Arq Gastroenterol; 2019; 56(4):394-398. PubMed ID: 31800735
    [TBL] [Abstract][Full Text] [Related]  

  • 67. "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    Kramer L; Laurain A; Sultanik P; Trémeaux P; Méritet JF; Rosenberg AR; Pol S
    J Hepatol; 2017 Dec; 67(6):1340-1342. PubMed ID: 28843657
    [No Abstract]   [Full Text] [Related]  

  • 68. Vedroprevir in the management of hepatitis C virus infection.
    Abutaleb A; Kottilil S
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1399-1402. PubMed ID: 29053394
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
    Burchill MA; Roby JA; Crochet N; Wind-Rotolo M; Stone AE; Edwards MG; Dran RJ; Kriss MS; Gale M; Rosen HR
    PLoS One; 2017; 12(10):e0186213. PubMed ID: 29040318
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    Halfon P; Scholtès C; Izopet J; Larrat S; Trimoulet P; Zoulim F; Alric L; Métivier S; Leroy V; Ouzan D; de Lédinghen V; Mohamed S; Pénaranda G; Khiri H; Thélu MA; Plauzolles A; Chiche L; Bourlière M; Abravanel F
    J Hepatol; 2018 Mar; 68(3):595-597. PubMed ID: 28987520
    [No Abstract]   [Full Text] [Related]  

  • 71. A novel variant of genotype 7b hepatitis C virus emphasizing viral hepatitis elimination challenges for sub-Saharan Africa.
    Sonderup MW; Smuts H; Spearman CW
    Pan Afr Med J; 2020; 36():232. PubMed ID: 33708323
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Second generation direct-acting antivirals - Do we expect major improvements?
    Feld JJ; Foster GR
    J Hepatol; 2016 Oct; 65(1 Suppl):S130-S142. PubMed ID: 27641983
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.
    Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438
    [TBL] [Abstract][Full Text] [Related]  

  • 74. NS5A inhibitors to treat hepatitis C virus infection.
    Welzel TM; Zeuzem S
    Lancet Infect Dis; 2012 Sep; 12(9):648-9. PubMed ID: 22714000
    [No Abstract]   [Full Text] [Related]  

  • 75. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.
    Reau N; Fried MW; Nelson DR; Brown RS; Everson GT; Gordon SC; Jacobson IM; Lim JK; Pockros PJ; Reddy KR; Sherman KE
    Liver Int; 2016 Apr; 36(4):488-502. PubMed ID: 26509462
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mexican consensus on the diagnosis and management of hepatitis C infection.
    Sánchez-Ávila JF; Dehesa-Violante M; Méndez-Sánchez N; Bosques-Padilla F; Castillo-Barradas M; Castro-Narro G; Cisneros-Garza L; Chirino-Sprung RA; García-Juarez I; Gonzalez-Huezo MS; Malé-Velazquez R; Moreno-Alcántar R; Muñoz-Espinoza L; Ramos-Gómez M; Rizo-Robles MT; Sandoval-Salas R; Sierra-Madero J; Torres-Ibarra Mdel R; Vazquez-Frias R; Wolpert-Barraza E; ; ;
    Ann Hepatol; 2015; 14 Suppl 1():5-48. PubMed ID: 25983318
    [No Abstract]   [Full Text] [Related]  

  • 77. Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options.
    Loggi E; Vukotic R; Andreone P
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):833-838. PubMed ID: 30336699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pro: Direct-acting antivirals are associated with occurrence and recurrence of hepatocellular carcinoma.
    Trotter JF
    Liver Transpl; 2017 Dec; 23(12):1593-1595. PubMed ID: 29024516
    [No Abstract]   [Full Text] [Related]  

  • 79. Interferon-free hepatitis C therapy: how close are we?
    Pockros PJ
    Drugs; 2012 Oct; 72(14):1825-31. PubMed ID: 22934796
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatitis C beware--the end is nigh.
    Gane E
    Lancet; 2014 Nov; 384(9954):1557-60. PubMed ID: 25078308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.